US Bancorp DE Buys New Shares in Ardent Health Partners, LLC (NYSE:ARDT)

US Bancorp DE purchased a new stake in shares of Ardent Health Partners, LLC (NYSE:ARDT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,834 shares of the company’s stock, valued at approximately $31,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. R Squared Ltd bought a new position in shares of Ardent Health Partners in the fourth quarter worth about $37,000. BNP Paribas Financial Markets purchased a new position in Ardent Health Partners in the 3rd quarter worth approximately $42,000. New York State Common Retirement Fund bought a new position in Ardent Health Partners in the 4th quarter worth approximately $48,000. MetLife Investment Management LLC purchased a new stake in Ardent Health Partners during the 3rd quarter valued at approximately $135,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Ardent Health Partners during the third quarter valued at approximately $154,000.

Ardent Health Partners Trading Up 1.1 %

NYSE ARDT opened at $14.24 on Wednesday. Ardent Health Partners, LLC has a one year low of $13.19 and a one year high of $20.72. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.91 and a quick ratio of 1.78. The company’s 50-day simple moving average is $14.67 and its two-hundred day simple moving average is $16.54.

Ardent Health Partners (NYSE:ARDT) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.31. The business had revenue of $1.61 billion for the quarter, compared to analysts’ expectations of $1.48 billion. Analysts forecast that Ardent Health Partners, LLC will post 1.23 earnings per share for the current year.

Analysts Set New Price Targets

ARDT has been the subject of several research reports. JPMorgan Chase & Co. reissued a “neutral” rating and set a $20.00 price objective on shares of Ardent Health Partners in a report on Tuesday, December 17th. Morgan Stanley decreased their target price on Ardent Health Partners from $23.50 to $22.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st. Stephens restated an “overweight” rating and set a $22.00 price target on shares of Ardent Health Partners in a report on Thursday, February 27th. Truist Financial reduced their price objective on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, Royal Bank of Canada decreased their target price on shares of Ardent Health Partners from $23.00 to $21.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Ardent Health Partners currently has a consensus rating of “Buy” and a consensus price target of $21.18.

About Ardent Health Partners

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.